FEC100 治疗患者化疗所致恶心和呕吐（CINV）的风险分析。
Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
机构信息
Breast Center, Dokkyo Medical University, Tochigi, Japan
Department of Medical Informatics, Niigata University, Niigata, Japan.
出版信息
Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596.
BACKGROUND/AIM: Risk factors for chemotherapy-induced nausea and vomiting (CINV) with anthracycline-containing regimen for breast cancer patients remain unknown. The risk factors for CINV with FEC100 were investigated.
PATIENTS AND METHODS
Data on CINV events and patient backgrounds of 180 patients were collected from the first cycle of FEC100 treatment. In this regimen, patients were administered various antiemetics (ADs). The combinations of ADs were classified into four categories, while body mass index (BMI) was stratified into three categories. Risk factors were selected based on patient characteristics and combination of ADs. Risks for CINV were analyzed by univariate and multivariate analyses.
RESULTS
In the univariate analysis of nausea, BMI was a significant factor, while BMI and combination of ADs were significant in vomiting. In the multivariate analysis concerning nausea, BMI was a significant factor. In the analysis concerning vomiting, the combination of ADs and BMI were significant.
CONCLUSION
BMI was the most important risk factor for nausea and vomiting, while the combination of ADs was for vomiting.
背景/目的：含蒽环类药物的乳腺癌化疗方案引起的恶心和呕吐（CINV）的风险因素尚不清楚。本研究旨在调查 FEC100 方案中 CINV 的风险因素。
方法
收集了 180 例接受 FEC100 治疗的患者的 CINV 事件和患者背景数据。在该方案中，患者使用了不同的止吐药物（ADs）。根据 AD 的组合将其分为四类，并将体重指数（BMI）分为三类。基于患者特征和 AD 的组合选择风险因素。通过单因素和多因素分析评估 CINV 的风险。
结果
在恶心的单因素分析中，BMI 是一个显著的因素，而在呕吐的单因素分析中，BMI 和 AD 的组合是显著的。在关于恶心的多因素分析中，BMI 是一个显著的因素。在关于呕吐的多因素分析中，AD 的组合和 BMI 是显著的。
结论
BMI 是恶心和呕吐最重要的风险因素，而 AD 的组合是呕吐的风险因素。
Zotero 插件